Sept. 8, 2022 Price forecast | 2 weeks: -0.43% | 1 month: -0.91% | 3 months: 16.84% | Premium Forecast


PBYI stock forecast

Our latest prediction for Puma Biotechnology Inc's stock price was made on the Sept. 8, 2022 when the stock price was at 2.56$.

In the short term (2weeks), PBYI's stock price should underperform the market by -0.43%. During that period the price should oscillate between -9.25% and +9.71%.

In the medium term (3months), PBYI's stock price should outperform the market by 16.84%. During that period the price should oscillate between -21.27% and +46.29%.

Create a solid portfolio with PBYI

Add PBYI to your portfolio and optimize it!


About Puma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

At the moment the company generates 66M USD in revenues.

On its last earning announcement, the company reported a loss of -29126.15$ per share.

The book value per share is 1.01$

Puma Biotechnology Inc website


Three months stock forecastSept. 8, 2022


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
66M 321.16% 9M 13.66% -34M -29126.15 - - 45M 1.01 - - -